In the mix: the potential benefits of adding GM-CSF to CpG-B in the local treatment of patients with early-stage melanoma.

Authors :: Koster, Bas D.
de Jong, Tamarah D.
van den Hout, Mari F. C. M.
Sluijter, Berbel J. R.
Vuylsteke, Ronald J. C. L. M.
Molenkamp, Barbara G.
Vosslamber, Saskia
van den Tol, M. Petrousjka
van den Eertwegh, Alfons J. M.
de Gruijl, Tanja D.
Source :: OncoImmunology. 2020, Vol. 9 Issue 1, p1-11. 11p.
Publication Year :: 2020
Abstract: Whereas TLR9 agonists are recognized as powerful stimulators of antitumor immunity, GM-CSF has had mixed reviews. In previously reported randomized trials we assessed the effects of local immune modulation in early-stage melanoma with CpG-B alone or with GM-CSF. Here we discuss the added value of GM-CSF and show sex-related differences. [ABSTRACT FROM AUTHOR]

Full Text Access

Tools